Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Acta Oncol 2019 Jul 17;58(7):967-976. Epub 2019 Apr 17.

a Institute of Neurology , Medical University of Vienna , Vienna , Austria.

Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups. Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Prognostic factors and treatment-related data were integrated in a comprehensive survival analysis including conditional survival estimates. We find variable patterns of first-line treatment with increasing use of rituximab and high-dose methotrexate (HDMTX)-based poly-chemotherapy after 2007, paralleled by an increase in median overall survival restricted to patients aged below 70 years. In the entire cohort, 5-year overall survival was 24.4% while 5-year conditional survival increased with every year postdiagnosis. In conclusion, we show that the use of poly-chemotherapy and immunotherapy has disseminated to community practice to a fair extent and survival has increased over time at least in younger patients. Annually increasing conditional survival rates provide clinicians with an adequate and encouraging prognostic measure.

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1599137DOI Listing
July 2019
22 Reads

Publication Analysis

Top Keywords

conditional survival
12
survival
9
cns lymphoma
8
primary cns
8
younger patients
8
survival increased
8
data integrated
4
year postdiagnosis
4
treatment death
4
lines treatment
4
postdiagnosis conclusion
4
2010 lines
4
death follow-up
4
prognostic factors
4
increased year
4
treatment-related data
4
2005 2010
4
follow-up 12-31-2016
4
12-31-2016 prognostic
4
factors treatment-related
4

Similar Publications